Roles of mitochondrial transporters SLC25A22 and SLC25A46 in brain health
Official title: Unraveling the roles of SLC25A22 and SLC25A46 in mitochondrial metabolism and neurological disorders
Funded at Oklahoma Medical Research Foundation · NIH-11515601 · Data updated 2026-11-12
This grant studies how two mitochondrial transporters, SLC25A22 and SLC25A46, affect brain metabolism and neurological disorders using fruit-fly models to uncover disease mechanisms.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oklahoma Medical Research Foundation NIH-funded |
| Lab location | 1 site (Oklahoma City, United States) |
| Project start | September 11, 2026 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $170,500 |
| NIH project number | 1R03NS147002-01A1 |
| Project ID | NIH-11515601 on NIH RePORTER |
Who could benefit from this research
✓Could help
Individuals with disorders linked to SLC25A46 or SLC25A22 mutations or related neuro-metabolic brain conditions may benefit from future therapies informed by this research.
✕Less likely to help
The immediate animal-model work will not directly treat patients, but aims to illuminate mechanisms that could lead to treatments later.
What this research studies
Researchers will create and study fruit-fly models of the human mitochondrial transporters SLC25A46 and SLC25A22 to understand how their loss disrupts brain metabolism. They will use advanced genetic tools to observe neuron-specific effects, mitochondrial shape, and brain-related energy pathways. By profiling metabolites, especially branched-chain amino acids, the project aims to connect mitochondrial transport defects with neurodevelopmental issues seen in patients. The work intends to build foundational knowledge that could inform future therapies for related neurological disorders.
Why it matters
Potential benefit: Better understanding of how mitochondrial transport defects cause neurological problems could guide development of targeted therapies for affected patients.
How similar studies have gone: Previous studies in model organisms have linked SLC25A family dysfunction to mitochondrial and neurological anomalies, supporting the approach's relevance.
Where this research is happening
-
Oklahoma Medical Research Foundation
Oklahoma City, United States Active
Researchers
- Principal investigator: Yoon, Wan Hee — Oklahoma Medical Research Foundation
- Study coordinator: Yoon, Wan Hee
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.